Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Vera Therapeutics (NASDAQ:VERA) shares surged 64% after positive late-stage trial results for atacicept in treating IgA ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

Company to host conference call and webcast on June 9, 2025, at 8:00 a.m. ETSAN FRANCISCO and VANCOUVER, British Columbia, ...